| Trial ID: | L2423 |
| Source ID: | NCT02516657
|
| Associated Drug: |
Liraglutide
|
| Title: |
Liraglutide in Adolescents With Type 1 Diabetes
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes
|
| Interventions: |
DRUG: Liraglutide
|
| Outcome Measures: |
Primary: Mean weekly blood glucose, The primary outcome is to determine whether liraglutide decreases mean weekly blood glucose in adolescents with Type 1 diabetes, 2 weeks | Secondary: Total Daily insulin dose, U/kg/day, 2 weeks | Other: Blood sugar < 70 mg/dL, Determine whether liraglutide increases episodes of blood sugar \<70 mg/dL as measured by glucometer and CGM, 2 weeks|Amylase level, Determine amylase levels during liraglutide treatment, 2 weeks
|
| Sponsor/Collaborators: |
Sponsor: University at Buffalo
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
5
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2012-05
|
| Completion Date: |
2024-12
|
| Results First Posted: |
|
| Last Update Posted: |
2022-03-09
|
| Locations: |
UBMD Pediatrics, Division of Pediatric Endocrinology, Buffalo, New York, 14203, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02516657
|
